Letrozole Amarox

Letrozole, the active ingredient in Letrozole Amarox, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat estrogen receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole Amarox is an aromatase inhibitor indicated for conditions within the hormone‑dependent breast cancer pathway. - Estrogen receptor‑positive breast cancer (postmenopausal): reduces tumor growth by lowering systemic estrogen levels. - Adjuvant therapy after surgery: helps prevent disease recurrence in eligible patients. - Metastatic breast cancer (postmenopausal): slows disease progression and may improve survival.

Adverse reactions may occur with Letrozole Amarox use.

Common Side Effects: - Hot flashes: transient episodes of warmth and sweating. - Joint pain: mild to moderate arthralgia. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe liver injury: signs of hepatitis or jaundice. - Bone fracture: increased risk due to reduced estrogen. - Pulmonary embolism: sudden shortness of breath. - Allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors. - Monitor bone health: assess osteoporosis risk and consider calcium/vitamin D supplementation. - Assess liver function: periodic liver enzyme testing is recommended. - Check cardiovascular status: be aware of potential thromboembolic events. - Avoid use in pregnancy: contraindicated due to teratogenic potential. - Store at ambient temperature: keep in the original pack, protect from moisture.

Letrozole may interact with several concomitant medications.

Major Interactions (Avoid): - Tamoxifen: concurrent use reduces the efficacy of both agents. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma concentrations. - Estrogen‑containing hormone therapy: antagonistic effect diminishes therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may alter anticoagulant effect; monitor INR. - Statins: potential impact on lipid profile; observe cholesterol levels. - SSRIs (e.g., fluoxetine): may increase risk of QT prolongation.